Labetuzumab: Difference between revisions
m Protected "Labetuzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 33: | Line 33: | ||
{{Humanizedmonoclonals}} | {{Humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 16:45, 9 August 2012
WikiDoc Resources for Labetuzumab |
Articles |
---|
Most recent articles on Labetuzumab Most cited articles on Labetuzumab |
Media |
Powerpoint slides on Labetuzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Labetuzumab at Clinical Trials.gov Clinical Trials on Labetuzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Labetuzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Labetuzumab Discussion groups on Labetuzumab Patient Handouts on Labetuzumab Directions to Hospitals Treating Labetuzumab Risk calculators and risk factors for Labetuzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Labetuzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Labetuzumab is a humanized monoclonal antibody used to treat cancer.